ABT vs. MRNA: A Head-to-Head Stock Comparison

Updated on July 7, 2025

Here’s a clear look at ABT and MRNA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Overview

ABT’s market capitalization of 233.90 billion USD is substantially larger than MRNA’s 11.79 billion USD, indicating a significant difference in their market valuations.

MRNA carries a higher beta at 1.86, indicating it’s more sensitive to market moves, while ABT (beta: 0.74) exhibits greater stability.

Symbol	ABT	MRNA
Company Name	Abbott Laboratories	Moderna, Inc.
Country	US	US
Sector	Healthcare	Healthcare
Industry	Medical - Devices	Biotechnology
CEO	Robert B. Ford	Stephane Bancel
Price	134.44 USD	30.49 USD
Market Cap	233.90 billion USD	11.79 billion USD
Beta	0.74	1.86
Exchange	NYSE	NASDAQ
IPO Date	March 17, 1980	December 7, 2018
ADR	No	No

Historical Performance

This chart compares the performance of ABT and MRNA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.

Data is adjusted for dividends and splits.

ABT vs. MRNA: Growth of a $10,000 investment over the past one year.

Profitability

Return on Equity

ABT

30.76%

Medical - Devices Industry

Max: 49.04%
Q3: 9.53%
Median: -7.46%
Q1: -32.83%
Min: -82.64%

In the upper quartile for the Medical - Devices industry, ABT’s Return on Equity of 30.76% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

MRNA

-30.10%

Biotechnology Industry

Max: 72.39%
Q3: -6.30%
Median: -32.82%
Q1: -68.26%
Min: -147.61%

MRNA has a negative Return on Equity of -30.10%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ABT vs. MRNA: A comparison of their ROE against their respective Medical - Devices and Biotechnology industry benchmarks.

Return on Invested Capital

ABT

19.13%

Medical - Devices Industry

Max: 21.88%
Q3: 6.63%
Median: -1.11%
Q1: -21.08%
Min: -51.95%

In the upper quartile for the Medical - Devices industry, ABT’s Return on Invested Capital of 19.13% signifies a highly effective use of its capital to generate profits when compared to its peers.

MRNA

-33.11%

Biotechnology Industry

Max: 48.74%
Q3: -10.68%
Median: -31.65%
Q1: -52.92%
Min: -113.69%

MRNA has a negative Return on Invested Capital of -33.11%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.

ABT vs. MRNA: A comparison of their ROIC against their respective Medical - Devices and Biotechnology industry benchmarks.

Net Profit Margin

ABT

31.89%

Medical - Devices Industry

Max: 44.80%
Q3: 9.77%
Median: -5.53%
Q1: -29.37%
Min: -87.68%

A Net Profit Margin of 31.89% places ABT in the upper quartile for the Medical - Devices industry, signifying strong profitability and more effective cost management than most of its peers.

MRNA

-106.27%

Biotechnology Industry

Max: 87.75%
Q3: -5.05%
Median: -103.44%
Q1: -1,032.77%
Min: -2,366.07%

MRNA has a negative Net Profit Margin of -106.27%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

ABT vs. MRNA: A comparison of their Net Profit Margin against their respective Medical - Devices and Biotechnology industry benchmarks.

Operating Profit Margin

ABT

16.97%

Medical - Devices Industry

Max: 30.13%
Q3: 13.12%
Median: 3.47%
Q1: -24.42%
Min: -80.56%

An Operating Profit Margin of 16.97% places ABT in the upper quartile for the Medical - Devices industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

MRNA

-118.04%

Biotechnology Industry

Max: 87.75%
Q3: -3.28%
Median: -115.26%
Q1: -1,188.86%
Min: -2,943.30%

MRNA has a negative Operating Profit Margin of -118.04%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

ABT vs. MRNA: A comparison of their Operating Margin against their respective Medical - Devices and Biotechnology industry benchmarks.

Profitability at a Glance

Symbol	ABT	MRNA
Return on Equity (TTM)	30.76%	-30.10%
Return on Assets (TTM)	16.58%	-26.42%
Return on Invested Capital (TTM)	19.13%	-33.11%
Net Profit Margin (TTM)	31.89%	-106.27%
Operating Profit Margin (TTM)	16.97%	-118.04%
Gross Profit Margin (TTM)	55.89%	52.55%

Financial Strength

Current Ratio

ABT

1.78

Medical - Devices Industry

Max: 12.68
Q3: 6.30
Median: 4.05
Q1: 1.85
Min: 0.01

ABT’s Current Ratio of 1.78 falls into the lower quartile for the Medical - Devices industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

MRNA

4.22

Biotechnology Industry

Max: 28.73
Q3: 13.97
Median: 6.31
Q1: 3.60
Min: 0.02

MRNA’s Current Ratio of 4.22 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

ABT vs. MRNA: A comparison of their Current Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Debt-to-Equity Ratio

ABT

0.27

Medical - Devices Industry

Max: 2.34
Q3: 1.09
Median: 0.37
Q1: 0.08
Min: 0.00

ABT’s Debt-to-Equity Ratio of 0.27 is typical for the Medical - Devices industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

MRNA

0.07

Biotechnology Industry

Max: 0.46
Q3: 0.22
Median: 0.06
Q1: 0.02
Min: 0.00

MRNA’s Debt-to-Equity Ratio of 0.07 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ABT vs. MRNA: A comparison of their D/E Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Interest Coverage Ratio

ABT

15.39

Medical - Devices Industry

Max: 18.18
Q3: 7.53
Median: 0.85
Q1: -9.80
Min: -33.94

ABT’s Interest Coverage Ratio of 15.39 is in the upper quartile for the Medical - Devices industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

MRNA

-207.17

Biotechnology Industry

Max: 108.32
Q3: -0.55
Median: -8.49
Q1: -74.83
Min: -168.36

MRNA has a negative Interest Coverage Ratio of -207.17. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

ABT vs. MRNA: A comparison of their Interest Coverage against their respective Medical - Devices and Biotechnology industry benchmarks.

Financial Strength at a Glance

Symbol	ABT	MRNA
Current Ratio (TTM)	1.78	4.22
Quick Ratio (TTM)	1.27	4.14
Debt-to-Equity Ratio (TTM)	0.27	0.07
Debt-to-Asset Ratio (TTM)	0.16	0.06
Net Debt-to-EBITDA Ratio (TTM)	0.60	0.27
Interest Coverage Ratio (TTM)	15.39	-207.17

Growth

The following charts compare key year-over-year (YoY) growth metrics for ABT and MRNA. These metrics are based on the companies’ annual financial reports.

Revenue Growth

ABT vs. MRNA: A comparison of their annual year-over-year Revenue Growth.

Earnings Per Share (EPS) Growth

ABT vs. MRNA: A comparison of their annual year-over-year Earnings Per Share (EPS) Growth.

Free Cash Flow Growth

ABT vs. MRNA: A comparison of their annual year-over-year Free Cash Flow Growth.

Dividend

Dividend Yield

ABT

1.70%

Medical - Devices Industry

Max: 3.57%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

With a Dividend Yield of 1.70%, ABT offers a more attractive income stream than most of its peers in the Medical - Devices industry, signaling a strong commitment to shareholder returns.

MRNA

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MRNA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ABT vs. MRNA: A comparison of their Dividend Yield against their respective Medical - Devices and Biotechnology industry benchmarks.

Dividend Payout Ratio

ABT

28.92%

Medical - Devices Industry

Max: 102.12%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ABT’s Dividend Payout Ratio of 28.92% is in the upper quartile for the Medical - Devices industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

MRNA

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MRNA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ABT vs. MRNA: A comparison of their Payout Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Dividend at a Glance

Symbol	ABT	MRNA
Dividend Yield (TTM)	1.70%	0.00%
Dividend Payout Ratio (TTM)	28.92%	0.00%

Valuation

Price-to-Earnings Ratio

ABT

17.40

Medical - Devices Industry

Max: 90.56
Q3: 56.92
Median: 43.19
Q1: 21.79
Min: 5.55

In the lower quartile for the Medical - Devices industry, ABT’s P/E Ratio of 17.40 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

MRNA

-3.51

Biotechnology Industry

Max: 78.44
Q3: 48.98
Median: 20.50
Q1: 12.64
Min: 2.14

MRNA has a negative P/E Ratio of -3.51. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.

ABT vs. MRNA: A comparison of their P/E Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Forward P/E to Growth Ratio

ABT

1.73

Medical - Devices Industry

Max: 6.56
Q3: 3.52
Median: 2.22
Q1: 0.55
Min: 0.03

ABT’s Forward PEG Ratio of 1.73 is within the middle range of its peers in the Medical - Devices industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.

MRNA

0.13

Biotechnology Industry

Max: 2.29
Q3: 1.10
Median: 0.49
Q1: 0.16
Min: 0.02

In the lower quartile for the Biotechnology industry, MRNA’s Forward PEG Ratio of 0.13 is a positive indicator. It suggests that the stock may be attractively valued relative to its expected earnings growth.

ABT vs. MRNA: A comparison of their Forward PEG Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Price-to-Sales Ratio

ABT

5.52

Medical - Devices Industry

Max: 15.74
Q3: 8.12
Median: 3.40
Q1: 2.37
Min: 0.42

ABT’s P/S Ratio of 5.52 aligns with the market consensus for the Medical - Devices industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

MRNA

3.73

Biotechnology Industry

Max: 110.90
Q3: 59.76
Median: 11.33
Q1: 4.45
Min: 0.17

In the lower quartile for the Biotechnology industry, MRNA’s P/S Ratio of 3.73 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

ABT vs. MRNA: A comparison of their P/S Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Price-to-Book Ratio

ABT

4.81

Medical - Devices Industry

Max: 16.65
Q3: 8.03
Median: 3.73
Q1: 1.92
Min: 0.65

ABT’s P/B Ratio of 4.81 is within the conventional range for the Medical - Devices industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

MRNA

1.17

Biotechnology Industry

Max: 15.78
Q3: 7.44
Median: 3.31
Q1: 1.58
Min: 0.31

The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.

ABT vs. MRNA: A comparison of their P/B Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Valuation at a Glance

Symbol	ABT	MRNA
Price-to-Earnings Ratio (P/E, TTM)	17.40	-3.51
Forward PEG Ratio (TTM)	1.73	0.13
Price-to-Sales Ratio (P/S, TTM)	5.52	3.73
Price-to-Book Ratio (P/B, TTM)	4.81	1.17
Price-to-Free Cash Flow Ratio (P/FCF, TTM)	35.14	-2.93
EV-to-EBITDA (TTM)	21.49	-3.42
EV-to-Sales (TTM)	5.68	3.45